StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Non-GAAP operating margin by Quarter

Non-GAAP operating margin (%) (%)

QuarterlyAnnual

Gilead Sciences Non-GAAP operating margin: -133.2% in Q2 2026, down 168.1 pts from a year earlier. That is the lowest of the 39 quarters on record here.

Latest, Q2 2026
-133.2%
Period ended Jun 30, 2026
Change on a year earlier
-168.1 pts
34.9% in Q2 2025
History
39 quarters
Since Q4 2016
Sources
34
Documents cited below

Where the Q2 2026 figure comes from

“|| Operating margin | (133.2) | % | 34.9 | % | (52.9) | % | 34.3 | %”

Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗

Reported in Form 8-K Reconciliation of GAAP to Non-GAAP Financial Information.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP operating margin (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-133.2%-168.1 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202637.2%+3.6 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 202525.0%-7.4 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2025Sep 30, 202542.8%+31.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202534.9%-3.1 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202533.6%+98.2 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2024Dec 31, 202432.4%+9.7 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2024Sep 30, 202411.8%-25.4 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 202438.0%+12.8 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-08-07) ↗
Q1 2024Mar 31, 2024-64.6%-99.9 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 202322.7%-13.8 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
Q3 2023Sep 30, 202337.2%-9.5 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-11-06) ↗
Q2 2023Jun 30, 202325.2%-17.5 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-08-08) ↗
Q1 2023Mar 31, 202335.3%-18.2 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 202236.5%+15.7 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗
Q3 2022Sep 30, 202246.7%-5.1 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2023-11-07) ↗

Breakdown

What makes up non-GAAP operating margin

Cite this data

StockData. (2026). Gilead Sciences Non-GAAP operating margin (%), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng-op-margin-pct

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.